Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04991571
Other study ID # D4325C00003
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 29, 2021
Est. completion date October 22, 2021

Study information

Verified date November 2021
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan. Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapagliflozin after dosing with two different fixed-dose combination (FDC) formulations and dosing with separate formulations of zibotentan and dapagliflozin.


Description:

Part 1 will be an open-label, non-randomised, single treatment period. A single treatment period during which participants will be resident at the study centre from 2 days before dosing (Day -2) until the morning of Day 6. Part 2 will be an open-label, randomised, 3-period, 3-treatment, cross-over single dose study. Participants will be randomised to one of 3 treatment sequences and will receive 3 single-dose study interventions. Participants will be resident at the study centre from 2 days before dosing (Day -2) until Day 3 of the last treatment sequence. Participants who were enrolled in Part 1 may not be enrolled in Part 2.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date October 22, 2021
Est. primary completion date October 22, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: For inclusion in the study participants should fulfil the following criteria: 1. Participants with suitable veins for cannulation or repeated venipuncture. 2. Females must have a negative pregnancy test at the Screening Visit and within 24 hours prior to dosing, must not be lactating and must be of non- childbearing potential 3. Male participant must adhere to the contraception methods. 4. Have a BMI between 18 and 29.9 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. 5. Provision of signed and dated, written informed consent prior to any study specific procedures. Exclusion Criteria: Participants will not enter the study if any of the following exclusion criteria are fulfilled: 1. History or presence of gastrointestinal, hepatic or renal disease or any important disease or disorder. 2. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention. 3. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis. 4. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and Human immunodeficiency virus antibody. 5. Abnormal vital signs. 6 History of drug abuse or alcohol abuse. 7. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity. 8. Participants who are vegans or have medical dietary restrictions. 9. Participants tested positive for COVID-19 at the time of randomisation or have been previously hospitalised with COVID-19 infection.

Study Design


Intervention

Drug:
Zibotentan (Treatment A)
Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
Dapagliflozin (Treatment A)
Dapagliflozin tablet will be administered orally as single dose in Part 2.
Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.

Locations

Country Name City State
United States Research Site Brooklyn Maryland

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Metabolites in Safety Testing sampling Plasma sample will be collected to understand the PK profiling of zibotentan metabolites and to meet the regulatory requirements. Day 1 through Day 6 (pre-dose, 30 min; 1, 2, 4, 6, 8, 12 and 24 hours post dose)
Primary Part 2: Area under plasma concentration time curve from zero to infinity (AUCinf) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Primary Part 2: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Primary Part 2: Maximum observed plasma drug concentration (Cmax) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Primary Part 2: Observed concentration at 24 hours post-dose (C24) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 2: Time to reach peak or maximum observed concentration (tmax) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 2: Terminal rate constant (?z) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 2: Half life associated with ?z (t½?z) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 2: Apparent total body clearance of drug from plasma after extravascular administration (CL/F) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 2: Volume of distribution at steady state following extravascular administration (Vz/F) Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated. Day 1 through Day 3 of each treatment period
Secondary Part 1 and Part 2: Number of adverse events and serious adverse events Safety and tolerability of zibotentan and dapagliflozin will be studied. From Sceerning to Follow-up Visit approximately 40 days for Part 1 and 49 days for Part 2
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4